Therefore, we suggest that β2M should be considered in future studies aiming to develop models for DLBCL as it is related to factors of prognostic importance for survival in lymphoma patients reflecting greater tumor burden (advanced clinical stage, extranodal sites, bulky disease, and serum LDH level) in addition to increased age and creatinine levels. This evidence concerns the gene B2M and neoplasm.